At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 9, 2026 at 08:00 ET
Keros Therapeutics presented additional Phase 1 data for rinvatercept (KER-065) at a clinical conference, showing target engagement, favorable changes in muscle and bone mass, and a good safety profile in healthy volunteers. The data support advancing rinvatercept into two Phase 2 trials for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), representing a meaningful step in the clinical development of the drug.
- Keros presented additional Phase 1 data for rinvatercept in healthy volunteers, confirming target engagement and mechanism of action.
- Rinvatercept was well-tolerated with no serious adverse events or dose-limiting toxicities.
- Treatment led to increased muscle mass, decreased fat mass, and improved bone mineral density.
- Proteomic data showed anti-fibrotic and anti-inflammatory effects, aligning with preclinical findings.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access